<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">761</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2025-12-1-84-95</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Search for associations of polymorphic variants of the <italic>MTHFR, MET, CHEK2</italic> genes, identified through next-generation sequencing, with cervical cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Поиск ассоциаций полиморфных вариантов генов <italic>MTHFR, MET, CHEK2</italic>, идентифицированных в ходе секвенирования нового поколения, с раком шейки матки</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5903-0085</contrib-id><name-alternatives><name xml:lang="en"><surname>Lenkova</surname><given-names>K. V.</given-names></name><name xml:lang="ru"><surname>Ленкова</surname><given-names>К. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p> Kseniya Vyacheslavovna Lenkova </p><p>71 Oktyabrya Prospekt, Ufa 450054, Russia </p></bio><bio xml:lang="ru"><p>Ксения Вячеславовна Ленкова  </p><p>Россия, 450054 Уфа, пр-кт Октября, 71</p></bio><email>ms.kv.kl@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5542-9531</contrib-id><name-alternatives><name xml:lang="en"><surname>Minyazeva</surname><given-names>R. M.</given-names></name><name xml:lang="ru"><surname>Минязева</surname><given-names>Р. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>3 Leninа St., Ufa 450008, Russia </p></bio><bio xml:lang="ru"><p>Россия, 450008 Уфа, ул. Ленина, 3</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1874-0774</contrib-id><name-alternatives><name xml:lang="en"><surname>Akhmetova</surname><given-names>V. L.</given-names></name><name xml:lang="ru"><surname>Ахметова</surname><given-names>В. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>71 Oktyabrya Prospekt, Ufa 450054, Russia;</p><p>12 Karl Marks St., Ufa 450008, Russia </p></bio><bio xml:lang="ru"><p>Россия, 450054 Уфа, пр-кт Октября, 71; </p><p>Россия, 450008 Уфа, ул. Карла Маркса, 12 </p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9499-5632</contrib-id><name-alternatives><name xml:lang="en"><surname>Gilyazova</surname><given-names>I. R.</given-names></name><name xml:lang="ru"><surname>Гилязова</surname><given-names>И. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>71 Oktyabrya Prospekt, Ufa 450054, Russia;</p><p>3 Leninа St., Ufa 450008, Russia;</p></bio><bio xml:lang="ru"><p>Россия, 450054 Уфа, пр-кт Октября, 71;</p><p>Россия, 450008 Уфа, ул. Ленина, 3 </p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8643-850X</contrib-id><name-alternatives><name xml:lang="en"><surname>Khusainova</surname><given-names>R. I.</given-names></name><name xml:lang="ru"><surname>Хусаинова</surname><given-names>Р. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>71 Oktyabrya Prospekt, Ufa 450054, Russia;</p><p>11 Dmitriya Ulyanova St., 117292 Moscow, Russia </p></bio><bio xml:lang="ru"><p>Россия, 450054 Уфа, пр-кт Октября, 71 </p><p>Россия, 117292 Москва, ул. Дмитрия Ульянова, 11 </p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7045-8215</contrib-id><name-alternatives><name xml:lang="en"><surname>Minniakhmetov</surname><given-names>I. R.</given-names></name><name xml:lang="ru"><surname>Минниахметов</surname><given-names>И. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>11 Dmitriya Ulyanova St., 117292 Moscow, Russia </p></bio><bio xml:lang="ru"><p>Россия, 117292 Москва, ул. Дмитрия Ульянова, 11 </p></bio><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Biochemistry and Genetics of the Ufa Federal Research Centre of the Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Институт биохимии и генетики ФГБНУ «Уфимский федеральный исследовательский центр Российской академии наук»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Bashkir State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Ufa University of Science and Technology</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Уфимский университет науки и технологий»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">National Medical Research Center of Endocrinology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2025</year></pub-date><volume>12</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>84</fpage><lpage>95</lpage><history><date date-type="received" iso-8601-date="2025-04-15"><day>15</day><month>04</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-04-15"><day>15</day><month>04</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Lenkova K.V., Minyazeva R.M., Akhmetova V.L., Gilyazova I.R., Khusainova R.I., Minniakhmetov I.R.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Ленкова К.В., Минязева Р.М., Ахметова В.Л., Гилязова И.Р., Хусаинова Р.И., Минниахметов И.Р.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Lenkova K.V., Minyazeva R.M., Akhmetova V.L., Gilyazova I.R., Khusainova R.I., Minniakhmetov I.R.</copyright-holder><copyright-holder xml:lang="ru">Ленкова К.В., Минязева Р.М., Ахметова В.Л., Гилязова И.Р., Хусаинова Р.И., Минниахметов И.Р.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/761">https://umo.abvpress.ru/jour/article/view/761</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>Worldwide, cervical cancer is the 4th most common cancer in women, and morbidity continues to grow. Supposedly, development of human papilloma virus-associated cervical cancer depends on genetic and epigenetic factors, but molecular pathogenesis of this pathology has not yet been established. Recently obtained data show that germline substitutions not only increase the risk of cancer but also affect tumor progression and form the picture of somatic changes in this malignant neoplasm.<bold>Aim. </bold>To investigate germline variants of the <italic>MTHFR</italic>, <italic>MET </italic>and <italic>CHEK2 </italic>genes and evaluate their significance in development of genetic predisposition towards cervical cancer.<bold>Materials and methods. </bold>DNA of 108 women with cervical cancer was analyzed. The comparison group included 51 patients with human papilloma virus elimination and 333 relatively healthy women. In the patient cohort, an analysis was performed using next-generation sequencing (NGS) and a custom panel aimed at genes participating in tumor designed by us. Additionally, clinical significance of the identified substitutions was evaluated using literature data, databases and bioinformatics methods. Additional association studies were performed for с.677С&gt;Т and с.1298A&gt;C variants of the <italic>MTHFR </italic>gene, c.2962C&gt;T variant of the <italic>MET </italic>gene, с.972G&gt;C variant of the <italic>CHEK2 </italic>gene.<bold>Results. </bold>It was observed that polymorphic variants с.972G&gt;C and c.1312С&gt;A of the <italic>CHEK2 </italic>gene have pathogenic potential. Among 11 substitutions in the <italic>MET </italic>gene identified during the study, variants c.2962C&gt;T, c.2975C&gt;T and c.3895G&gt;C are liable to be pathogenic. Correlations between T locus allele c.2962C&gt;T of the <italic>MET </italic>gene (<italic>p </italic>= 0.002; χ2 = 9.8) and C locus allele с.972G&gt;C of the <italic>CHEK2 </italic>gene (<italic>p </italic>= 0.05; χ2 = 3.8) with the risk of cervical cancer development were found.<bold>Conclusion. </bold>During the study, a group of germline substitutions in the <italic>MTHFR</italic>, <italic>MET </italic>and <italic>CHEK2 </italic>genes with unclear clinical significance was identified. It was shown that substitutions с.972G&gt;C and c.1312С&gt;A in the <italic>CHEK2 </italic>gene and c.2962C&gt;T, c.2975C&gt;T, c.3895G&gt;C in the <italic>MET </italic>gene have pathogenic potential in the context of cervical cancer. Additionally, previously unknown associations between loci c.2962C&gt;T of the <italic>MET </italic>gene and с.972G&gt;C of the <italic>CHEK2 </italic>gene with this pathology were described.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Рак шейки матки по распространенности занимает 4-е место среди злокачественных новообразований у женщин в мире, и заболеваемость им неуклонно растет. предполагается, что формирование ассоциированного с вирусом папилломы человека рака шейки матки зависит от генетических и эпигенетических факторов, однако молекулярный патогенез данной патологии еще не установлен. Недавно полученные данные свидетельствуют о том, что герминальные замены не только увеличивают риск развития рака, но и влияют на прогрессирование опухоли и формируют картину соматических изменений при злокачественном новообразовании.<bold>Цель исследования </bold>– поиск герминальных вариантов генов <italic>MTHFR</italic>, <italic>MET </italic>и <italic>CHEK2 </italic>и оценка их значимости в формировании генетической предрасположенности к раку шейки матки.<bold>Материалы и методы. </bold>проанализирована ДНк 108 женщин с раком шейки матки. В группу сравнения вошла 51 пациентка с элиминацией вируса папилломы человека и 333 условно здоровых женщины. В когорте больных проведено исследование с использованием методов секвенирования нового поколения (next generation sequencing NGS) и разработанной нами кастомной панели, нацеленной на гены, участвующие в опухолеобразовании. Также проанализирована клиническая значимость выявленных замен на основе данных литературы, баз данных и с помощью биоинформатических методов. Для вариантов с.677С&gt;Т и с.1298A&gt;C гена <italic>MTHFR</italic>, c.2962C&gt;T гена <italic>MET</italic>, c.972G&gt;C гена <italic>CHEK2 </italic>проведены дополнительные ассоциативные исследования.<bold>Результаты. </bold>Выявлено, что полиморфные варианты с.972G&gt;C и c.1312С&gt;A гена <italic>CHEK2 </italic>обладают патогенным потенциалом. из 11 обнаруженных в результате исследования замен в гене <italic>MET </italic>варианты c.2962C&gt;T, c.2975C&gt;T и c.3895G&gt;C являются вероятно патогенными. Выявлена ассоциация аллеля T локуса c.2962C&gt;T гена <italic>MET </italic>(<italic>p </italic>= 0,002; χ2 = 9,8) и аллеля С локуса с.972G&gt;C гена <italic>CHEK2 </italic>(<italic>p </italic>= 0,05; χ2 = 3,8) с риском развития рака шейки матки.<bold>Заключение. </bold>В ходе исследования выявлена группа герминальных замен в генах <italic>MTHFR</italic>, <italic>MET </italic>и <italic>CHEK2 </italic>с неясным клиническим значением. Определено, что патогенный потенциал в отношении формирования рака шейки матки имеют замены с.972G&gt;C и c.1312С&gt;A гена <italic>CHEK2 </italic>и c.2962C&gt;T, c.2975C&gt;T, c.3895G&gt;C гена <italic>MET</italic>. Также выявлены ранее не описанные ассоциации локусов c.2962C&gt;T гена <italic>MET </italic>и с.972G&gt;C гена <italic>CHEK2 </italic>с данной патологией.</p></trans-abstract><kwd-group xml:lang="en"><kwd>cervical cancer</kwd><kwd>genetic predisposition</kwd><kwd>oncogenetics</kwd><kwd>next-generation sequencing</kwd><kwd>human papilloma virus</kwd><kwd>MTHFR</kwd><kwd>MET</kwd><kwd>CHEK2</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак шейки матки</kwd><kwd>генетическая предрасположенность</kwd><kwd>онкогенетика</kwd><kwd>секвенирование нового поколения</kwd><kwd>вирус папилломы человека</kwd><kwd>MTHFR</kwd><kwd>MET</kwd><kwd>CHEK2</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>World Health Organization. Human papillomavirus and cancer Available at: https://www.who.int/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Beglyarzade S.A., Mukhametova R.R., Zhao B. Prospects for comprehensive screening and treatment of cervical cancer. Kreativnaya hirurgiya i onkologiya = Creative Surgery and Oncology 2024;14(1):60–8. (In Russ.). DOI: 10.24060/2076-3093-2024-14-1-60-68</mixed-citation><mixed-citation xml:lang="ru">Беглярзаде С.А., Мухаметова Р.Р., Жао Б. Перспективы комплексного скрининга и терапии рака шейки матки. Креативная хирургия и онкология 2024;14(1):60–8. DOI: 10.24060/2076-3093-2024-14-1-60-68</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Okunade K.S. Human papillomavirus and cervical cancer. J Obstet Gynaecol 2020;40(5):602–8. DOI: 10.1080/01443615.2019.1634030</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Bril Yu.A., Raevskaya O.A. “Higgs bosons” of cervical neoplasia. Ginekologiya, akusherstvo, besplodnyi brak = Gynecology, Obstetrics, Infertile marriage 2019;3:74–81. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Бриль Ю.А., Раевская О.А. «Бозоны Хиггса» цервикальной неоплазии. Гинекология, акушерство, бесплодный брак 2019; 3:74–81.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Lenkova K.V., Khusainova R.I., Minniakhmetov I.R. Molecular and genetic bases of cervical cancer. Molekulyarnaya meditsina = Molecular Medicine 2023;4:25–33. (In Russ.). DOI: 10.29296/24999490-2023-04-04</mixed-citation><mixed-citation xml:lang="ru">Ленкова К.В., Хусаинова Р.И., Минниахметов И.Р. Молекулярногенетические основы рака шейки матки. Молекулярная медицина 2023;4:25–33. DOI: 10.29296/24999490-2023-04-04</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Chanock S.J. How the germline informs the somatic landscape. Nat Genet 2021;53(11):1523–5. DOI: 10.1038/s41588-021-00960-6</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Srinivasan P., Bandlamudi C., Jonsson P. et al. The context-specific role of germline pathogenicity in tumorigenesis. Nat Genet 2021;53(11):1577–85. DOI: 10.1038/s41588-021-00949-1</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hajiesmaeil M., Tafvizi F., Sarmadi S. The effect of methylenetetrahydrofolate reductase polymorphisms on susceptibility to human papilloma virus infection and cervical cancer. Infect Genet Evol 2016;46:1–6. DOI: 10.1016/j.meegid.2016.10.012</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Yi K., Yang L., Lan Z. et al. The association between MTHFR polymorphisms and cervical cancer risk: a system review and meta analysis. Arch Gynecol Obstet 2016;294(3):579–88. DOI: 10.1007/s00404-016-4037-6</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Wang Z., Li K., Ouyang L. et al. Effects of methylenetetrahydrofolate reductase single-nucleotide polymorphisms on breast, cervical, ovarian, and endometrial cancer susceptibilities. Chronic Dis Transl Med 2021;12;7(3):169–81. DOI: 10.1016/j.cdtm.2021.06.003</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Stolarova L., Kleiblova P., Janatova M. et al. CHEK2 germline variantsin cancer predisposition: stalemate rather than checkmate. Cells 2020;12;9(12):2675. DOI: 10.3390/cells9122675</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Yang X., Liao H.Y., Zhang H.H. Roles of MET in human cancer. Clin Chim Acta 2022;15;525:69–83. DOI: 10.1016/j.cca.2021.12.017</mixed-citation></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Minniakhmetov I.R., Zabelin M.V., Olkov I.G. A pilot project for cervical cancer screening using HPV testing. Voprosy onkologii - Oncology Issues 2020;66(6):618–24. (In Russ.). DOI: 10.37469/0507-3758-2020-66-6-618-624</mixed-citation><mixed-citation xml:lang="ru">Минниахметов И.Р., Забелин М.В., Ольков И.Г. Пилотный проект по скринингу рака шейки матки с применением ВПЧ-тестирования. Вопросы онкологии 2020;66(6):618–24. DOI: 10.37469/0507-3758-2020-66-6-618-624</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><mixed-citation>Richards S., Aziz N., Bale S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17(5):405–24. DOI: 10.1038/gim.2015.30</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Abou Tayoun A.N., Pesaran T., DiStefano M.T. et al. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Hum Mutat 2018;39(11):1517–24. DOI: 10.1002/humu.23626</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Brnich S.E., Abou Tayoun A.N., Couch F.J. et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome Med 2019;12:3. DOI: 10.1186/s13073-019-0690-2</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Rodrigues C.H.M., Pires D.E.V., Ascher D.B. DynaMut2: assessing changes in stability and flexibility upon single and multiple point missense mutations. Protein Sci 2021;30(1):60–9. DOI: 10.1002/pro.3942</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Fleiss J.L., Levin B., Paik M.C. Statistical methods for rates and proportions 3rd edn. Hoboken, New Jersey John Wiley and Sons, Inc., 2003. 200 p.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Mo H.N., Liu P. Targeting MET in cancer therapy. Chronic Dis Transl Med 2017;19;3(3):148–53. DOI: 10.1016/j.cdtm.2017.06.002</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Qiu L., Feng H., Yu H. et al. Characterization of the genomic landscape in cervical cancer by next generation sequencing. Genes (Basel) 2022;13(2):287. DOI: 10.3390/genes13020287</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Wen H., Xu Q., Sheng X. et al. Prevalence and landscape of pathogenic or likely pathogenic germline variants and their association with somatic phenotype in unselected chinese patients with gynecologic cancers. JAMA Netw Open 2023;3;6(7):e2326437. DOI: 10.1001/jamanetworkopen.2023.26437</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Lenkova K., Khusainova R., Minyazeva R. et al. Germline variants in proto-oncogenes and tumor suppressor genes in women with cervical cancer. Biomedicines 2024;12(11):2454. DOI: 10.3390/biomedicines12112454</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Kumpula T.A., Koivuluoma S., Soikkonen L. et al. Evaluating the role of CHEK2 p.(Asp438Tyr) allele in inherited breast cancer predisposition. Fam Cancer 2023;22(3):291–4. DOI: 10.1007/s10689-023-00327-2</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Tyner J.W., Fletcher L.B., Wang E.Q. et al. MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res 2010;1;70(15):6233–7. DOI: 10.1158/0008-5472.CAN-10-0429</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Agarwal D., Hatzis C., Pusztai L. Functional polymorphisms in cancer. Oncoscience 2015;20;2(2):73–4. DOI: 10.18632/oncoscience.129</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Guyard A., Danel C., Théou-Anton N. et al. Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. Respir Res 2017;15;18(1):120. DOI: 10.1186/s12931-017-0605-y</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>MTjin E.P., Groen R.W., Vogelzang I. et al. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 2006;15;107(2):760–8. DOI: 10.1182/blood-2005-05-1929</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Ma P.C., Kijima T., Maulik G. et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;1;63(19):6272–81.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Liu S., Meric-Bernstam F., Parinyanitikul N. et al. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget 2015;20;6(5):2604–14. DOI: 10.18632/oncotarget.309</mixed-citation></ref></ref-list></back></article>
